ES2164109T3 - Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf. - Google Patents

Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.

Info

Publication number
ES2164109T3
ES2164109T3 ES94927076T ES94927076T ES2164109T3 ES 2164109 T3 ES2164109 T3 ES 2164109T3 ES 94927076 T ES94927076 T ES 94927076T ES 94927076 T ES94927076 T ES 94927076T ES 2164109 T3 ES2164109 T3 ES 2164109T3
Authority
ES
Spain
Prior art keywords
beta
piperidinilcarbonil
alanina
derivatives
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927076T
Other languages
English (en)
Inventor
Mitsuru Ohkubo
Fumie Takahashi
Toshio Yamanaka
Hiroyoshi Sakai
Masayuki Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319561A external-priority patent/GB9319561D0/en
Priority claimed from GB9413936A external-priority patent/GB9413936D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2164109T3 publication Critical patent/ES2164109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL INVENTO SE REFIERE A DERIVADOS DE BETA-ALANINA REPRESENTADOS POR LA FORMULA (I) EN DONDE CADA SIMBOLO ES COMO SE DEFINE EN LAS ESPECIFICACIONES Y A SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO QUE ES ANTAGONISTA DE LA GLICOPROTEINA IIB/IIIA, INHIBIDOR DE LA AGREGACION PLAQUETARIA DE LA SANGRE E INHIBIDOR DEL ENLACE DE FIBRINOGENO A LAS PLAQUETAS DE LA SANGRE, A PROCESOS PARA LA PREPARACION DEL MISMO, A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL MISMO Y A UN METODO PARA LA PREVENCION Y/O TRATAMIENTO DE ENFERMEDADES INDICADAS EN LA ESPECIFICACION EN UN SER HUMANO O EN UN ANIMAL.
ES94927076T 1993-09-22 1994-09-21 Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf. Expired - Lifetime ES2164109T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939319561A GB9319561D0 (en) 1993-09-22 1993-09-22 Beta-alanine derivative and a process for preparation thereof
GB9413936A GB9413936D0 (en) 1994-07-11 1994-07-11 Beta-Alanine derivative and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
ES2164109T3 true ES2164109T3 (es) 2002-02-16

Family

ID=26303555

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927076T Expired - Lifetime ES2164109T3 (es) 1993-09-22 1994-09-21 Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.

Country Status (16)

Country Link
US (1) US6380215B1 (es)
EP (2) EP0669912B1 (es)
CN (1) CN1041919C (es)
AT (1) ATE210118T1 (es)
AU (1) AU684547B2 (es)
CA (1) CA2157792C (es)
DE (1) DE69429328T2 (es)
DK (1) DK0669912T3 (es)
ES (1) ES2164109T3 (es)
HK (1) HK1004985A1 (es)
HU (1) HUT73174A (es)
IL (3) IL126825A (es)
PT (1) PT669912E (es)
RU (1) RU2161155C2 (es)
TW (1) TW401414B (es)
WO (1) WO1995008536A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051730A1 (en) * 1993-09-22 2001-12-13 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivative and a process for the preparation thereof
KR19980703107A (ko) * 1995-03-17 1998-10-15 후지야마 아키라 N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도
WO1997033869A1 (en) * 1996-03-13 1997-09-18 Fujisawa Pharmaceutical Co., Ltd. N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
SI0923555T1 (en) * 1996-05-01 2005-10-31 Ortho-Mcneil Pharmaceutical, Inc. Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders
PL190796B1 (pl) * 1996-05-01 2006-01-31 Ortho Mcneil Pharm Inc Karboksyamidowe pochodne piperydyny do leczenia zaburzeń zakrzepicowych
CA2296428A1 (en) * 1997-07-14 1999-01-28 John Neilsen Piperidine oligomers and combinatorial libraries thereof
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
WO1999025685A1 (en) * 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU769718B2 (en) * 1998-10-12 2004-02-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing beta-alanine derivative
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DK1165543T3 (da) * 1999-03-22 2003-09-29 Ortho Mcneil Pharm Inc Fremgangsmåde til fremstilling af [S-(R*,S*)]-G(B)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinpropansyre og derivater deraf
ES2244474T3 (es) 1999-09-29 2005-12-16 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamida para el tratamiento de trastornos mediados por integrina.
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
WO2005079863A1 (ja) 2004-02-25 2005-09-01 Astellas Pharma Inc. 血栓造影剤
MX352546B (es) 2011-08-17 2017-11-29 Piramal Imaging Sa Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.
JP2016508507A (ja) 2013-02-12 2016-03-22 バイエル・ファルマ・アクティエンゲゼルシャフト 血小板特異的糖タンパク質ＩＩｂ／ＩＩＩａに結合するための金属キレート化合物
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03257624A (ja) * 1990-03-08 1991-11-18 Fujitsu Ltd 画面言語方式
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
CA2054627A1 (en) * 1991-02-13 1992-08-14 Yea-Shun Cheng Polypeptide skeletal muscle relaxants
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds

Also Published As

Publication number Publication date
EP1106606A2 (en) 2001-06-13
EP1106606A3 (en) 2003-10-22
RU2161155C2 (ru) 2000-12-27
US6380215B1 (en) 2002-04-30
HK1004985A1 (en) 1998-12-18
DK0669912T3 (da) 2002-03-04
IL126825A (en) 1999-09-22
CN1116847A (zh) 1996-02-14
EP0669912B1 (en) 2001-12-05
IL111036A0 (en) 1994-11-28
TW401414B (en) 2000-08-11
AU684547B2 (en) 1997-12-18
WO1995008536A1 (en) 1995-03-30
IL126825A0 (en) 1999-08-17
CA2157792A1 (en) 1995-03-30
IL111036A (en) 1999-07-14
DE69429328T2 (de) 2002-06-13
EP0669912A1 (en) 1995-09-06
PT669912E (pt) 2002-03-28
CN1041919C (zh) 1999-02-03
AU7665794A (en) 1995-04-10
DE69429328D1 (de) 2002-01-17
RU95112456A (ru) 1997-04-20
CA2157792C (en) 2005-05-24
HU9501845D0 (en) 1995-08-28
ATE210118T1 (de) 2001-12-15
HUT73174A (en) 1996-06-28

Similar Documents

Publication Publication Date Title
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
PT816376E (pt) Inibidores de trombina como agentes anticoagulantes
NO882036L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske ketoner.
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
FI950309A0 (fi) Proliiniamidijohdannaisia
WO2005056524A3 (en) Therapeutic agents useful for treating pain
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
SE0002729D0 (sv) Novel compound form
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
SE0102058D0 (sv) New Salts II
EA200300900A1 (ru) Замещенные амины (варианты), способ их получения и их применение в качестве ингибиторов транспорта глицина (варианты), композиция (варианты), промежуточный иодид и способ его получения, способ лечения пациента (варианты)
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669912

Country of ref document: ES